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Abstract In the present study, we examined the relation-
ship between Beclin-1 expression and HIF-1α expression
in esophageal squamous cell carcinoma(ESCC). There was
a loss of Beclin-1 protein expression in 33% of ESCCs.
Beclin-1 expression significantly correlated with depth of
invasion, lymph node metastasis and clinical stage. Among
the 54 patients, The survival rate of the Beclin-1-positive
group was better than that of the Beclin-1-negative group.
Twenty-five of the 54 (46%) tumor specimens showed high
levels of HIF-1α immunoreactivity. Beclin-1 expression
was associated with HIF-1α expression. The survival rate
of patients with Beclin-1-positive and HIF-1α-low tumors
was significantly higher than that of the other groups. These
results suggest that Beclin-1 and HIF-1α expression are
important determinants of survival in ESCCs.
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Introduction
Programmed cell death (PCD) is an essential and highly
orchestrated process that plays a major role in morphogen-
esis and tissue homeostasis. Apoptosis, the type I PCD, is
a well characterized caspase-dependent process. While
autophagy, a vacuolar process of cytoplasmic degradation,
is characterized by autophagic vacuoles accumulating, no
apoptosis body forming, and no chromosome condensing
and caspase independence. Thus, autophagic cell death is
considered PCD type II [1, 2]. Autophagy is becoming an
important area in cancer research, but data connecting
cancer pathogenesis with autophagic cell death are limited.
Whether autophagy in cancer cells causes death or protects
cells is controversial. Malignant transformation is frequently
associated with suppression of autophagy, however, the
opposite scenario has also been reported [3, 4].
Beclin-1, an essential mediator of autophagy, was origi-
nally discovered during the course of a yeast two-hybrid
screenofamousebraincDNAlibrary[5]. The human Beclin-
1 gene has been mapped to a tumor-susceptibility locus on
chromosome 17q21 that is monoallelically deleted in up to
75% of ovarian cancers, 50% of breast cancers, and 40% of
prostate cancers [6]. Moreover, Beclin-1
−/− mutant mice die
early in embryogenesis and Beclin-1
+/− mutant mice suffer
from a high incidence of spontaneous tumors, establishing
thatBeclin-1isacriticalcomponentofmammalianautophagy
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group [8] found a frequent loss of Beclin-1 protein
expression in breast cancers, and suggested that tumor
suppressor functions of Beclin-1 are lost in the cancer cells
by loss of protein expression. Ahn et al. [9]d e m o n s t r a t e d
that Beclin-1 may play a role in tumorigenesis for the
increased expression of Beclin-1 protein detected in the
malignant colorectal and gastric epithelial cells. These
contradictory results prompt us to analyse Beclin-1 protein
expression in human esophageal cancer tissues.
HIF-1α has been found to play important roles in tumor
growth and metastasis by regulating energy metabolism and
inducing angiogenesis in the survival against cellular
hypoxia. In various types of cancer, HIF-1α expression
was reported to be correlated with tumor growth, invasion
and metastases [10–13]. It was reported that autophagy
associates with hypoxia. Autophagic cell death is induced
by hypoxia in cancer cells with intact apoptotic machinery,
and HIF-1 serves to regulate autophagy in mouse embryo
fibroblasts [14–16]. However, there are no reports with
respect to the relationship between Beclin-1 and HIF-1α
expressions in human cancers. We therefore examined their
expressions in human squamous cell carcinoma of the
esophagus. The primary objective was to ascertain whether
Beclin-1 plays a role in tumor development and progression
associatedwithHIF-1α,assecondaryendpoints,weevaluated
the impact of their protein expressions on patient outcome.
Materials and Methods
Patients and Tissues
54 cases of esophagectomy specimens of primary esopha-
geal squamous cell carcinoma (ESCC) were collected from
the files of the Department of Pathology, West China
Hospital, Sichuan University, dating from January 2003 to
September 2004. All patients did not receive preoperative
chemoradiotherapy. This study was conducted in accor-
dance with ethical principles stated in the Declaration of
Helsinki, 1996 and informed consent for using esophageal
tissues was obtained from the patients or their families.
To determine an accurate staging, pathology reports and
clinical histories at the time of surgery were reviewed.
The clinicopathologic stage was according to the Interna-
tional Union Against Cancer (UICC) TNM classification
system [17]. Age, sex, tumor differentiation and TNM stage
(T: depth of tumor invasion, N: lymph node metastasis,
M: distant metastasis) were evaluated. The overall survival
times of the patients were measured from the date of
operation to the date of death or the last follow-up. The
patients were 38 males and 16 females and ranged in age
from 39 to 77 years (median: 61 years).
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissues (4 μm thick)
were immunostained using a Labelled Streptavidin Biotin 2
(LSAB2) System (BioGenex i6000, USA). Beclin-1 was
detected with a rabbit polyclonal antibody and HIF-1α was
detected with a mouse monoclonal antibody Mab (1:80
dilution for the anti-Beclin-1 antibody or 1:100 dilution for
the anti-HIF-1α antibody; Santa Cruz Biotechnology, Santa
Cruz, USA). After deparaffinization and rehydration, tissue
sections were incubated with 3% hydrogen peroxide in
methanol for 30 min to block endogeneous peroxidase
activity. The primary antibody reaction was carried out at
4°C overnight. Subsequent steps were performed accord-
ing to the manufacturer’s instructions. Diaminobenzidine-
tetrahydrochloride (DAB) was used as the substrate to
detect antigen-antibody binding, and the sections were
counterstained with Mayer’s haematoxylin.
Beclin-1 and HIF-1α immunoreactivity were detected in
normal epithelial cells of esophagus and squamous cell
carcinoma tissues. Expression of Beclin-1 was defined as
positive if distinct staining of the cytoplasm or cyto-
membrane was observed in at least 10% of tumor cells.
HIF-1α immunoreactivity was present in cytoplasm.
The percentages of cancer cells with cytoplasmic HIF-1α
localisation were assessed separately in all optical fields. The
mean value of the percentages obtained from all optical fields
examined in each case was used to calculate the cytoplasmic
scores for each case. These scores were used to calculate the
overall mean value and range of the percentages of cells with
HIF-1α localisation. The mean values for cytoplasmic
expression of HIF-1α were used as the cut-off points to
define two groups: high and low HIF-1α expression.
Statistical Analysis
Statistical evaluation was performed using the SPSS
software package (SPSS 16.0, SPSS Inc., Chicago, USA).
The Chi-square test was used to analyze the correlation
between Beclin-1 or HIF-1α expression and clinicopatho-
logic features. Cumulative survival rate was calculated by
the Kaplan–Meier method, and the significance of differ-
ences in survival rate was analyzed by the log-rank test.
The level of statistical significance was set at p<0.05.
Results
Relationship between Beclin-1 Expression
and Clinicopathological Features
Of the 54 ESCCs, immunoreactivity for Beclin-1 was not
detected in 18 cases (Fig. 1b). 36 (66.7%) showed positive
488 Y. Chen et al.Beclin-1 immunoreactivity in the cytoplasm and cyto-
membrane of cancer cells (Fig. 1c). While analyzing
clinicopathological factors, depth of invasion, lymph node
metastasis and clinical stage showed statistically significant
correlationswithBeclin-1expression; however,there was no
significant difference in Beclin-1 expression with respect to
other characteristics (sex, age and differentiation) (Table 1).
Beclin-1 was displayed positive immunoreactivity in normal
epithelial cells of all cases adjacent to squamous cell
carcinoma tissues (Fig. 1a).
Relationship between HIF-1α Expression
and Clinicopathological Features
HIF-1α immunoreactivity was not detected in normal
squamous cells of esophagus (Fig. 1d). HIF-1α staining
was observed mainly in the cytoplasm of the esophageal
cancer cells (Fig. 1e, f). The mean percentage of cells with
cytoplasmic HIF-1α immunoreactivity was 28.2% (range
5–80%). On the basis of the criteria described in Section 2,
25 of the 54 ESCCs(46.3%) were judged to have high
HIF-1α expression. HIF-1α immunoreactivity was corre-
lated significantly with differentiation, depth of invasion,
and clinical stage (Table 2).
Relationship between Beclin-1 and HIF-1α Expression
We analysed the association between Beclin-1 and HIF-1α
protein expression. In the 36 ESCCs marked as Beclin-
1-positive tumors, 24 were low-HIF-1α a n d1 2w e r e
high-HIF-1α. Whereas, in the 18 ESCCs classified as
Beclin-1-negative tumors, the low-HIF-1α and high-HIF-
1α tumors were 5 and 13, respectively. A significant
association was found between Beclin-1 and HIF-1α
expression (P=0.001, Table 3).
Cumulative Kaplan–Meier Survival Curve
The median follow-up period was 33.5 months with a range
from 11 to 56 months. The 1-, 2- and 3-year survival for
Fig. 1 Immunohistochemical analysis of Beclin-1 and HIF-1α in
esophageal squamous cell carcinoma. a Positive Beclin-1 immunore-
activity in cytoplasm of normal squamous epithelial cells. b Negative
Beclin-1 immunoreactivity in tumour cells. c Positive Beclin-1
immunoreactivity in cytoplasm and cytomembrane of tumour cells.
d In normal squamous epithelial cells, HIF-1α immunoreactivity was
not detected. e Weak HIF-1α immunoreactivity in cytoplasm of
tumour cells. f Strong HIF-1α immunoreactivity in tumour cells.
Original magnification: a, e and f, ×200; b and d, ×100; c, ×400
Beclin-1 and ESCC 489the entire patient group was 95.8%, 82.9% and 56.1%,
respectively. The survival rate of the Beclin-1-positive
group was better than that of the Beclin-1-negative group
(Fig. 2a). Furthermore, there was a tendency toward a
poorer outcome in patients with HIF-1α-high tumors
compared with that in patients with HIF-1α-low tumors,
however, differences were not statistically significant
(Fig. 2b). Bivariate analysis was also assessed in 37
patients. The survival rate of patients with Beclin-1-positive
and HIF-1α-low tumors (n=24) was significantly higher
than that of the other group (n=13) (Fig. 2c).
Discussion
Study showed that malignant cells frequently displayed
lower levels of basal autophagic activity than their normal
counterparts and failed to increase autophagic activity; in
addition, Beclin-1, an autophagy execution protein, was
viewed as a tumor suppressor protein [18]. In 1999, Liang
et al. [8] found that in 56% of breast cancers there was a
significant loss of Beclin-1 protein expression in cancer
cells compared to normal breast epithelial cells, later studies
reported that Beclin-1 was monoallelically deleted in
human prostate, cervical and ovarian cancers and was
expressed at reduced levels in those tumors [6, 8, 19].
Miracco et al. [20] recently examined the expression of
Beclin-1 protein in 212 primary human brain tumors, in
most high-grade astrocytic, ependymal neoplasms and
atypical meningiomas they found a decrease of Beclin-1
protein expression that was, instead, high in the majority of
low-grade tumors and in medulloblastomas. Which indi-
cates that Beclin-1 expression is related to the aggressive-
ness of brain tumors.
Furthermore, controversy regarding the roles of autophagy
incancerhasbeenemerged,studiesshowedthatBeclin-1play
different roles in cell death and cell survival depending on the
cellular context [21–23]. Koneri and his colleagues [24]
investigated the function of Beclin-1 gene in colorectal
cancer cell lines, transfection of the low Beclin-1 gene-
expressing colon cancer cell line with the Beclin-1 gene
resulted in cell growth inhibition, they concluded that
Beclin-1 can inhibit the growth of colorectal cancer cells.
Wang et al. [18] detected the role of Beclin-1 in HeLa cells
using RNA interference and they found that over-
expression of Beclin-1 promoted the autophagy cell
death but siRNA against Beclin-1 transfectants promoted
Table 3 Coincidental expressions of Beclin-1 and HIF-1α proteins in
ESCC
Beclin-1 P value
Positive Negative
Low HIF-1α 24 (36.9%) 5 (7.69%) 0.001
High HIF-1α 12 (18.5%) 13 (20%)
Table 2 Clinicopathological features and HIF-1α expression in
ESCC
Variables No. of cases HIF-1α expression P value
Low High
Gender
Male 38 23 15 0.121
Female 16 6 10
Age (years)
<60 30 13 17 0.088
≥60 24 16 8
Differentiation
Well 12 10 2 0.003
Moderate 20 13 7
Poor 22 6 16
T stage
T1, T2 25 24 1 <0.001
T3, T4 29 5 24
N stage
N0 26 17 9 0.097
N1 28 12 16
Clinical stage
I, II 22 17 5 0.004
III, IV 32 12 20
Table 1 Clinicopathological features and Beclin-1 expression in
ESCC
Variables No. of cases Beclin-1 expression P value
Positive Negative
Gender
Male 38 24 14 0.399
Female 16 12 4
Age (years)
<60 30 20 10 1.00
≥60 24 16 8
Differentiation
Well 12 10 2 0.351
Moderate 20 13 7
Poor 22 13 9
T stage
T1, T2 25 23 2 0.001
T3, T4 29 13 16
N stage
N0 26 24 2 <0.001
N1 28 12 16
Clinical stage
I, II 22 21 1 <0.001
III, IV 32 15 17
490 Y. Chen et al.the cell proliferation. These examples favor a cancer-
killing role for autophagy, overexpression of Beclin-1
induces cell death and defection of autophagy may be an
important mechanism in tumorigenesis. However, Amaravadi
[25] presented results supporting the idea that autophagy
can protect tumor cells from cell death stimuli. Daniel [23]
discovered that blockade of Beclin-1 expression aggravates
cell death in HepG2 cells. Ahn et al. [9] investigated Beclin-
1 protein expression in colorectal and gastric carcinoma
tissues, there was increased expression of Beclin-1 in the
malignant colorectal and gastric epithelial cells compared to
their normal mucosal epithelial cells. These studies provide
evidence that autophagy serves as a survival pathway in
tumor cells.
We detected Beclin-1 protein in squmous cell carcinoma
tissues of esophagus for the first time and found that there
was a loss of Beclin-1 protein expression in 33% of ESCCs
compared to normal esophageal epithelial cells. Moreover,
Beclin-1 immunoreactivity was correlated significantly
with depth of invasion, lymph node metastasis and clinical
stage, the survival curve of the Beclin-1 negative group was
worse than that of the Beclin-1 positive group. These
findings may indicate that Beclin-1 plays an important role
in development and progression of ESCC and is a factor
significantly influencing overall survival rate.
Studies revealed that HIF-1α expression was absent in
most normal tissues, and in human tumors, overexpression
of HIF-1α activated metabolic and pathogenic pathways
that were related to tumor angiogenesis, growth, invasion
and metastasis [10, 26, 27]. Moreover, HIF-1α expression
may play an important role in the progression of ESCC and
is associated with poor patient prognosis [11, 12]. In the
present study, HIF-1α immunoreactivity was not detected
in normal squamous esophageal epithelial cells and HIF-1α
expression was correlated significantly with differentiation,
depth of invasion, and clinical stage of ESCC. Our findings
are consistent with results from these previous studies.
There was a tendency for shorter survival in patients with
high HIF-1α expression, but this correlation did not reach
statistical significance, probably owing to short periods of
follow-up and the small number of patients enrolled in our
study.
Certain environmental cues (such as starvation, low
oxygen, hormonal stimulation) activate signalling pathways
that increase autophagy, which can either remove defective
structures or be as a means of providing macromolecules
Fig. 2 Cumulative Kaplan–Meier survival curves. a Curves for
patients with Beclin-1-positive tumors and Beclin-1-negative tumors.
b Curves for patients with HIF-1α-low tumors and HIF-1α-high
tumors. c Curves for patients with Beclin-1-positive and HIF-1α-low
tumors compared to patients with Beclin-1-negative and HIF-1α-
high tumors
R
Beclin-1 and ESCC 491for energy generation. HIF-1 activates transcription and
plays a critical role in oxygen homeostasis [28]. The
relationship between autophagy and hypoxia has been
interpreted. Previous study showed that autophagy is
associated with hypoxia during cardiac ischemia and
metabolic stress as a survival mechanism [29]. Azad et al.
[14] recently analyzed glioma cell lines, breast cancer cell
lines and embryonic cell line for cell death response in
hypoxia. Under hypoxic conditions, cell lines induced an
autophagic response and underwent cell death. By knocking
down the autophagy protein Beclin-1, hypoxia-induced cell
death was reduced, hypoxia-induced cell death was also
reduced upon treatment with the autophagy inhibitor 3-
methyladenine. This demonstrated that autophagic cell death
is induced by hypoxia in cancer cells. Zhang and his
colleagues [15] found that mitochondrial autophagy is an
adaptive metabolic response which is necessary to maintain
redox homeostasis and cell survival. In mouse embryo
fibroblasts, HIF-1 induces expression of BNIP3, which
triggers selective mitochondrial autophagy. Hypoxia can
induce mitochondrial autophagy and this process requires
the HIF-1-dependent expression of BNIP3 and the constitu-
tive expression of Beclin-1. Which suggests a close
relationship exists between Beclin-1 and HIF-1 [30].
There have been no reports on the association between
Beclin-1 and HIF-1α expression. Interestingly, Beclin-1
expression was associated with HIF-1α expression in our
immunohistochemical analysis. HIF-1α expression was
high while there was reduced expression of Beclin-1 in
late stage of ESCC, the survival curve of the Beclin-1
negative and high-HIF-1α group was worse than that of
the Beclin-1 positive and low-HIF-1α group. This study
indicates that Beclin-1 and HIF-1α proteins may play
important roles in the progression of ESCC and are factors
significantly influencing overall survival rate. There was a
tendency of Beclin-1-induced autophagy inhibition by high
expression of HIF-1α, which promotes tumor progression.
Additional studies are needed to clarify these association.
In conclusion, we found that Beclin-1 expression is
associated with HIF-1α expression. The Beclin-1 and HIF-
1α proteins appear to play important roles in the progres-
sion of human ESCC. Measuring Beclin-1 and HIF-1α
expression may contribute to a better understanding of the
prognosis of patients with ESCC, at least in a subset of
patients who had not received preoperative chemoradio-
therapy. Beclin-1 can be a potential target for the treatment
of ESCCs.
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